Adding ICIs to chemotherapy ± antiangiogenic therapy improves survival outcomes in advanced NSCLC that is resistant to EGFR-TKIs.

With EAGLE, lung cancer biopsy analysis is expedited, accurately predicting EGFR mutations and streamlining the diagnostic process for better patient outcomes.

Non-Small Cell Lung Cancer Market grows as immunotherapy approvals by Merck & Bristol-Myers reshape global treatment pathways. Anurag Tiwari Orion Market Research Pvt Ltd +91 91798 28694 email us here ...

They want to gain a deeper understanding of why the disease behaves differently in these patients. Read more at ...

This week’s edition of The Targeted Pulse spotlights 5 key developments shaping the landscape of targeted oncology.

With ever-growing treatment options, clinical care access and a new focus on integrative strategies, cancer centers are constantly upgrading their services and options for patients. Becker’s asked ...

An AI-based EGFR biomarker tool could preclude the need for a rapid PCR test in nearly half of advanced lung adenocarcinoma cases, a study has suggested.

Johnson & Johnson ( NYSE: JNJ) Q2 2025 Earnings Conference Call July 16, 2025 8:30 AM ET ...

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has awarded two new research grants to support studies on zipalertinib, a promising therapy for Non-Small ...

Quality-of-life in lung cancer varies, with certain treatments leading to sleep-related issues, pain, and emotional changes depending on disease stage.